Alexion Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on Alexion Pharmaceuticals Inc in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Alexion Pharmaceuticals Inc Strategy Report

  • Understand Alexion Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Alexion Pharmaceuticals Inc: Overview

Select Item

Alexion Pharmaceuticals Inc (Alexion), a subsidiary of AstraZeneca Plc, discovers, develops and markets therapies for severe and life-threatening diseases. The company’s brands comprise Kanuma, Koselug, Soliris, StrensIQ and Ultomiris among others. It develops medicines to treat conditions such as atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), hypophosphatasia (HPP), lysosomal acid lipase deficiency (LAL-D), neurofibromatosis type 1 plexiform neurofibromas (NF1 PN), neuromyelitis optica spectrum disorder (NMOSD) and paroxysmal nocturnal hemoglobinuria (PNH). Alexion’s therapeutic areas include hematology, nephrology, neurology, metabolics, cardiology and others. Alexion collaborates with various research organizations and pharmaceutical companies to develop treatments for rare and severe diseases. The company operates in Europe and the Middle East, North America, Latin America and Asia Pacific. Alexion is headquartered in Boston, Massachusetts, the US.

 Gain a 360-degree view of Alexion Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Alexion Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 121 Seaport Boulevard, Boston, Massachusetts, 02210
Website alexion.com
Telephone 1 475 2302596
No of Employees 3,000
Industry Pharmaceuticals and Healthcare
Revenue (2020) $6.1B
   
   
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Alexion Pharmaceuticals Inc premium industry data and analytics

290+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Alexion Pharmaceuticals Inc’s relevant decision makers and contact details.

260+

Clinical Trials

Determine Alexion Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

260+

Catalyst Calendar

Proactively evaluate Alexion Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

100+

Pipeline Drugs

Identify which of Alexion Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

60+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

18+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

5

Sales & Consensus Forecasts

Understand the current and future drug revenue for Alexion Pharmaceuticals Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

5

Marketed Drugs

Understand Alexion Pharmaceuticals Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Alexion Pharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline Kanuma
Ultomiris: Hematology and Neurology Koselug
Koselugo: Bone Metabolism Soliris
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Alexion Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Alexion Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In September, the company entered into a collaboration with Verge Genomics to identify novel drug targets for rare neurodegenerative and neuromuscular diseases.
2023 Contracts/Agreements In July, the company and AstraZeneca Rare Disease entered into an agreement to acquire a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc.
2023 Contracts/Agreements In May, the company entered into agreement with BioLight for the potential diagnosis of retinal diseases.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Alexion Pharmaceuticals Inc Novartis AG Amgen Inc Baxter International Inc Regeneron Pharmaceuticals Inc
Headquarters United States of America Switzerland United States of America United States of America United States of America
City Boston Basel Thousand Oaks Deerfield Tarrytown
State/Province Massachusetts - California Illinois New York
No. of Employees 3,000 76,057 26,700 60,000 13,450
Entity Type Private Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
Marc Dunoyer Chief Executive Officer Senior Management - -
Shane Doyle Head - Operations; Senior Vice President Senior Management - -
Lukasz Jarzyna Vice President - Global Access and Pricing Senior Management - -
Tamar Thompson Head - Corporate Affairs; Vice President Senior Management - -
Fred Chereau Senior Vice President - Strategy and Business Development Senior Management - -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Alexion Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Alexion Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward